The UK HVC has assembled diverse GMP HIV vaccine constructs (DNA plasmids, modified vaccinia, adenovirus vectors and protein) using common HIV antigens, and an adjuvant for wide HIV vaccine research. The programme is committed to unraveling the background IP such that all products can be made available to researchers, with freedom to use for non-commercial clinical research.